Evidence map›Paper›PMID 39619440›Full record

ArticleFrontiers in oncology2024

Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone.

Brenna C McAllister, Nooshin Mesbahi, Esther E Dodson, Sakinah Abdulsalam, Clifford E Berkman, Leslie A Caromile

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brenna C McAllisterCenter for Vascular Biology, University of Connecticut Health Center, Farmington, CT, United States.
Nooshin MesbahiDepartment of Chemistry, Washington State University, Pullman, WA, United States.
Esther E DodsonDepartment of Chemistry, Washington State University, Pullman, WA, United States.
Sakinah AbdulsalamDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT, United States.
Clifford E BerkmanDepartment of Chemistry, Washington State University, Pullman, WA, United States.
Leslie A CaromileCenter for Vascular Biology, University of Connecticut Health Center, Farmington, CT, United States.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
APP TRAFFICKING AND THE PATHWAYS OF A BETA FORMATIONR01AG012376 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOO, EDWARD H. · 1994 to 2007
$2.6M
Skeletal, Craniofacial and Oral Biology Training GrantT90DE033006 · NIDCR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI FRANK C NICHOLS · 2023 to 2026
$2.0M
PSMAs role in signal transduction pathway switching in prostate cancerK01CA188412 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CAROMILE, LESLIE ANN · 2014 to 2018
$502k
Frontiers in Bone Metastatic Models for Prostate CancerR21CA282396 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BERKMAN, CLIFFORD, CAROMILE, LESLIE ANN · 2024 to 2024
$423k
Near-IR Ratiometric Fluorescence Probes for Assessing Cargo Delivery to Prostate TumorsR21CA256382 · NCI · WASHINGTON STATE UNIVERSITY · PI BERKMAN, CLIFFORD, CAROMILE, LESLIE ANN · 2021 to 2022
$398k
Phosphatidylinositol phosphatase activity of Phogrin regulates insulin secretionF31DK081307 · NIDDK · UNIVERSITY OF WASHINGTON · PI CAROMILE, LESLIE ANN · 2008 to 2009
$46k
NCI NIH HHS K01 CA188412NCI NIH HHS P30 CA047904NCI NIH HHS R21 CA256382NCI NIH HHS R21 CA282396NIA NIH HHS R01 AG012376NIDCR NIH HHS T90 DE033006NIDDK NIH HHS F31 DK081307
6 · The paper itself

Abstract

Giant cell tumor of bone (GCTB) is a rare bone tumor often necessitating surgical intervention, radiation therapy, or treatment with bisphosphonates or denosumab.

Indexed as

giant cell tumor of bone (GCTB)LocametzPluvictoprostate specific membrane antigen (PSMA)repurposable drugs

Identifiers

PMID39619440
PMCPMC11604636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.